BOSTON July 1, 2024’ Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company dedicated to advancing new medicines for patients with cancer, has announced pivotal achievements that underscore its commitment to cancer research and its expanding influence in the biopharmaceutical sector.
Inclusion in the Russell 3000 and Russell Microcap Indexes’
In a significant recognition of its recent progress and growing market footprint, Verastem Oncology will be added to the Russell 3000 and Russell Microcap Indexes, effective at the open of U.S. equity VSTM Monday, July 1, 2024. This inclusion is part of the 2024 Russell U.S. Indexes annual reconstitution.
Russell Indexes are widely regarded benchmarks in the investment community, and being part of these indices can greatly enhance a company’s visibility and attract potential investors. The inclusion demonstrates the financial community’s growing confidence in Verastem Oncology’s strategic direction and potential for future growth.
Promising Results from RAMP 205 Clinical Trial’
Furthermore, Verastem Oncology has released promising initial interim safety and efficacy results from its ongoing RAMP 205 Phase 1/2 clinical trial. This trial evaluates avutometinib and defactinib in combination with gemcitabine and Nab-paclitaxel for first-line treatment of patients with metastatic pancreatic cancer.
As of May 14, 2024, the data revealed encouraging outcomes for patients receiving this combination treatment. The initial results bolster the potential of avutometinib and defactinib as a promising therapeutic duo, further fortifying the company’s innovative approach to developing new cancer therapies.
First Quarter 2024 Financial Performance and Business Highlights’
Adding to the recent wave of positive news, Verastem Oncology also reported robust financial performance and significant business developments for the first quarter ended March 31, 2024. During this period, the company achieved FDA Orphan Drug Designation for the combination of avutometinib and defactinib in recurrent low-grade serous ovarian cancer. This designation is a critical milestone, recognizing the combination as a unique therapeutic approach distinct from other cancer forms.
“Our inclusion in the Russell Indexes, coupled with the promising initial results from our clinical trials and strong financial performance, marks a period of significant advancement for Verastem Oncology,” said the company’s CEO. “We remain dedicated to our mission of developing novel therapies to improve the lives of cancer patients and believe these milestones reaffirm our commitment and potential to make a meaningful impact in the oncology field.”
Conclusion’
Verastem Oncology’s recent achievements highlight its progress and potential within the biopharmaceutical industry. The inclusion in the Russell 3000 and Russell Microcap Indexes, coupled with promising clinical trial results and financial performance, positions the company for continued success in its mission to combat cancer.
Comments